NYSE:ZYME Zymeworks (ZYME) Stock Price, News & Analysis $12.57 +0.05 (+0.40%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$12.18 -0.40 (-3.14%) As of 04/25/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock About Zymeworks Stock (NYSE:ZYME) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Zymeworks alerts:Sign Up Key Stats Today's Range$12.23▼$12.5850-Day Range$9.44▼$14.8252-Week Range$8.21▼$17.70Volume370,378 shsAverage Volume614,750 shsMarket Capitalization$874.58 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingModerate Buy Company OverviewZymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.Read More… Zymeworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreZYME MarketRank™: Zymeworks scored higher than 55% of companies evaluated by MarketBeat, and ranked 534th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingZymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageZymeworks has only been the subject of 3 research reports in the past 90 days.Read more about Zymeworks' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zymeworks are expected to decrease in the coming year, from ($1.39) to ($1.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zymeworks is -8.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zymeworks is -8.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZymeworks has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Zymeworks' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ZYME. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZymeworks does not currently pay a dividend.Dividend GrowthZymeworks does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for ZYME. News and Social Media4.0 / 5News Sentiment1.22 News SentimentZymeworks has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Zymeworks this week, compared to 5 articles on an average week.Search Interest4 people have searched for ZYME on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat Follows2 people have added Zymeworks to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Zymeworks insiders have bought more of their company's stock than they have sold. Specifically, they have bought $16,137,499.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.92% of the stock of Zymeworks is held by insiders.Percentage Held by Institutions92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zymeworks' insider trading history. Receive ZYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter. Email Address ZYME Stock News HeadlinesZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 73,953 SharesApril 19, 2025 | insidertrades.comEcor1 Capital, Llc Buys 196,438 Shares of Zymeworks Inc. (NYSE:ZYME) StockApril 8, 2025 | insidertrades.comNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America. April 28, 2025 | Paradigm Press (Ad)Zymeworks Inc. (NYSE:ZYME) Director Purchases $51,664.75 in StockApril 3, 2025 | insidertrades.comInsider Buying: Zymeworks Inc. (NYSE:ZYME) Director Purchases 43,848 Shares of StockMarch 28, 2025 | insidertrades.comZymeworks Inc.: Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual MeetingApril 26 at 12:26 PM | finanznachrichten.deZymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual MeetingApril 25 at 1:00 PM | globenewswire.comZymeworks Strengthens Clinical Leadership with New Senior VP AppointmentApril 21, 2025 | tipranks.comSee More Headlines ZYME Stock Analysis - Frequently Asked Questions How have ZYME shares performed this year? Zymeworks' stock was trading at $14.64 on January 1st, 2025. Since then, ZYME stock has decreased by 14.1% and is now trading at $12.57. View the best growth stocks for 2025 here. How were Zymeworks' earnings last quarter? Zymeworks Inc. (NYSE:ZYME) issued its quarterly earnings data on Thursday, October, 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.01. Zymeworks's revenue was down 3.1% on a year-over-year basis. When did Zymeworks IPO? Zymeworks (ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager. Who are Zymeworks' major shareholders? Zymeworks' top institutional investors include Assenagon Asset Management S.A. (0.71%), SG Americas Securities LLC (0.14%), Rhumbline Advisers (0.12%) and Ritholtz Wealth Management (0.09%). Insiders that own company stock include Ecor1 Capital, Llc, Kenneth Galbraith, Neil A Klompas, Paul Andrew Moore, Neil Josephson, Jeffrey T L Smith and Christopher Astle. View institutional ownership trends. How do I buy shares of Zymeworks? Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zymeworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings10/31/2024Today4/27/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNYSE:ZYME Previous SymbolNASDAQ:ZYME CIK1937653 Webwww.zymeworks.com Phone(302) 274-8744Fax604-737-7077Employees460Year FoundedN/APrice Target and Rating Average Stock Price Target$21.00 High Stock Price Target$30.00 Low Stock Price Target$13.00 Potential Upside/Downside+67.1%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-118,670,000.00 Net Margins-182.75% Pretax Margin-189.75% Return on Equity-23.00% Return on Assets-18.04% Debt Debt-to-Equity RatioN/A Current Ratio4.10 Quick Ratio4.10 Sales & Book Value Annual Sales$76.30 million Price / Sales11.46 Cash FlowN/A Price / Cash FlowN/A Book Value$6.63 per share Price / Book1.90Miscellaneous Outstanding Shares69,577,000Free Float67,556,000Market Cap$874.58 million OptionableOptionable Beta1.18 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NYSE:ZYME) was last updated on 4/28/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.